Overall rank by patents
#25,829
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Axon Neuroscience SE
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
10
Total patents granted
6
CPC technology areas
26.7
Avg claims per patent
-33%
5-year filing velocity
The verdict
Axon holds 10 US patents across 6 technology areas, rank #25,829 of 50,000 tracked assignees.
- #25,829
- of 50,000 US assignees by volume
- Top 50%
- by Innovation Score (35.3/100)
- 26.7
- avg claims per patent
- -33%
- filing velocity, last 5 yrs
Portfolio overview
Axon Neuroscience SE has been granted 10 US utility patents between 2015 and 2025, placing Axon Neuroscience SE at rank #25,829 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Axon Neuroscience SE is one of the more focused assignees in the PatentsView dataset. By volume, Axon sits between Avere Systems, Inc. (10 patents, rank #25,825) and B2B Casuals, Inc. (10 patents, rank #25,833) - the closest US assignees by grant volume. The composite Innovation Score of 35.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 6 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Axon Neuroscience SE's 26.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Axon Neuroscience SE against peers pursuing similar technology classes.
Who files at Axon's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Avere Systems
Avere Systems, Inc.
10 patents
- Avocado Systems
Avocado Systems, Inc.
10 patents
- Axine Water
Axine Water Technologies Inc.
10 patents
- Axis Spine
Axis Spine Technologies Ltd.
10 patents
- Axus Technology
Axus Technology, LLC
10 patents
- Ayasdi
Ayasdi, Inc.
10 patents
- Aylus Networks
Aylus Networks, Inc.
10 patents
- B2B Casuals
B2B Casuals, Inc.
10 patents
- Axon Neuroscience… ◀
Axon Neuroscience SE
10 patents
What this shows Axon holds 10 patents at rank #25,829, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Axon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 50% higher than 50% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 10.0% |
| 2016 | 2 | 20.0% |
| 2017 | 2 | 20.0% |
| 2018 | 1 | 10.0% |
| 2020 | 1 | 10.0% |
| 2021 | 1 | 10.0% |
| 2022 | 1 | 10.0% |
| 2025 | 1 | 10.0% |
Which technologies does Axon Neuroscience SE patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Axon Neuroscience SE hold?
Axon Neuroscience SE holds 10 US granted patents filed between 2015 and 2025, spanning 6 technology areas.
What is Axon Neuroscience SE's Innovation Score?
Axon Neuroscience SE has an Innovation Score of 35.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Axon Neuroscience SE focus on?
Axon Neuroscience SE's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 10 patents. The company has filed patents in 6 CPC subclasses total.
Is Axon Neuroscience SE's patent filing rate increasing or decreasing?
Axon Neuroscience SE's recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Axon Neuroscience SE's patents?
Axon Neuroscience SE's patents average 26.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Axon Neuroscience SE patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Axon's 10 grants land it in the top 50% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Axon ranks #25,829 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.